Pipeline — registered trials by phase
No registered trials in this stage.
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
— · Locally Advanced Solid Tumor, Metastatic Solid Tumor · Recruiting · est. 2027-01
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
— · Locally Advanced Solid Tumor, Metastatic Solid Tumor · Recruiting · est. 2027-12
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
— · Locally Advanced Solid Tumor, Metastatic Solid Tumor · Recruiting · est. 2027-12-31
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
— · Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive · Recruiting · est. 2029-12
JideytroZidesamtinib
Source: ClinicalTrials.gov (trials where Nuvalent is lead sponsor; 4 active or completed) and Drugs@FDA (1 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- No filings found.
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.